Abstract
In individuals with asthma, chronic use of short (SABAs) and long-acting beta-2 agonists (LABAs) can lead to loss of bronchoprotection (LOBP) from direct and indirect stimuli.1-3 It is hypothesized that LOBP is the result of beta-2 receptor down-regulation, reduced production or internalization of receptors, and uncoupling from secondary messengers leading to desensitization of beta-2 receptors.4 Assessment of beta-2 receptor activation is a laborious process.5 Therefore, a biomarker that serves as an indirect method of measuring beta-2 receptor activation would facilitate clinical studies on beta-2 agonist-induced LOBP and beta-2 receptor desensitization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
